Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.

Ring, Kari L; Pakish, Janelle; Jazaeri, Amir A

Ring, Kari L; Pakish, Janelle; Jazaeri, Amir A.

Affiliation

Ring KL; From the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.K.L.R. and J.P. contributed equally to the current review.

Cancer J ; 22(2): 101-7, 2016.

Article in En | MEDLINE | ID: mdl-27111905

Subject(s)

Antineoplastic Agents/therapeutic use; Genital Neoplasms, Female/drug therapy; Genital Neoplasms, Female/immunology; Immunomodulation/drug effects; Molecular Targeted Therapy; Animals; Antibodies, Monoclonal/pharmacology; Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/pharmacology; B7-H1 Antigen/antagonists & inhibitors; B7-H1 Antigen/metabolism; CTLA-4 Antigen/antagonists & inhibitors; CTLA-4 Antigen/metabolism; Clinical Trials as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Female; Genital Neoplasms, Female/diagnosis; Genital Neoplasms, Female/mortality; Humans; Programmed Cell Death 1 Receptor/antagonists & inhibitors; Programmed Cell Death 1 Receptor/metabolism; T-Lymphocyte Subsets/drug effects; T-Lymphocyte Subsets/immunology; T-Lymphocyte Subsets/metabolism; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Immunomodulation / Molecular Targeted Therapy / Genital Neoplasms, Female / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies Language: En Journal: Cancer J Year: 2016 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google